X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1018) 1018
Book Review (163) 163
Publication (35) 35
Book Chapter (4) 4
Conference Proceeding (4) 4
Magazine Article (4) 4
Dissertation (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (896) 896
humans (809) 809
diabetes mellitus, type 2 - drug therapy (654) 654
sitagliptin phosphate (586) 586
male (579) 579
hypoglycemic agents - therapeutic use (516) 516
sitagliptin (510) 510
female (474) 474
pyrazines - therapeutic use (436) 436
triazoles - therapeutic use (435) 435
middle aged (421) 421
dipeptidyl-peptidase iv inhibitors - therapeutic use (382) 382
type 2 diabetes (365) 365
endocrinology & metabolism (328) 328
aged (324) 324
diabetes (311) 311
sitagliptin phosphate - therapeutic use (256) 256
treatment outcome (253) 253
animals (232) 232
diabetes mellitus, type 2 - blood (227) 227
adult (208) 208
hypoglycemic agents (202) 202
metformin (200) 200
dipeptidyl peptidase-4 inhibitor (197) 197
drug therapy, combination (197) 197
pharmacology & pharmacy (192) 192
glucagon-like peptide-1 (191) 191
glucose (188) 188
glycemic control (187) 187
hypoglycemic agents - adverse effects (186) 186
metformin - therapeutic use (175) 175
blood glucose - metabolism (169) 169
blood glucose - drug effects (166) 166
double-blind (162) 162
dipeptidyl-peptidase iv inhibitors - pharmacology (159) 159
care and treatment (150) 150
pyrazines - pharmacology (150) 150
triazoles - pharmacology (148) 148
glycated hemoglobin a - metabolism (147) 147
hypoglycemic agents - administration & dosage (147) 147
insulin (146) 146
pyrazines - adverse effects (144) 144
triazoles - adverse effects (142) 142
safety (140) 140
adamantane - analogs & derivatives (138) 138
efficacy (135) 135
diabetes mellitus (134) 134
hypoglycemic agents - pharmacology (128) 128
double-blind method (125) 125
pyrazines - administration & dosage (121) 121
triazoles - administration & dosage (121) 121
analysis (116) 116
dipeptidyl-peptidase iv inhibitors - adverse effects (115) 115
adamantane - therapeutic use (111) 111
medicine, general & internal (110) 110
mellitus (108) 108
rats (108) 108
mice (102) 102
diabetes mellitus, type 2 - complications (100) 100
research (99) 99
peptides - therapeutic use (98) 98
diabetes therapy (95) 95
venoms - therapeutic use (95) 95
drug therapy (93) 93
internal medicine (91) 91
beta-cell function (89) 89
abridged index medicus (85) 85
dosage and administration (85) 85
glucagon (85) 85
glycated hemoglobin a - analysis (84) 84
dextrose (83) 83
medicine, research & experimental (83) 83
vildagliptin (82) 82
clinical trials (81) 81
dipeptidyl-peptidase iv inhibitors - administration & dosage (79) 79
monotherapy (79) 79
sitagliptin phosphate - pharmacology (78) 78
therapy (78) 78
liraglutide (77) 77
sitagliptin phosphate - adverse effects (77) 77
dipeptidyl peptidase 4 - metabolism (76) 76
hyperglycemia (76) 76
dipeptidyl peptidase-4 inhibitors (75) 75
insulin resistance (74) 74
nitriles - therapeutic use (74) 74
pyrrolidines - therapeutic use (74) 74
type-2 diabetes-mellitus (74) 74
diabetes mellitus, type 2 - metabolism (73) 73
glp-1 (73) 73
risk factors (70) 70
peptides (69) 69
sitagliptin phosphate - administration & dosage (68) 68
diabetes mellitus, type 2 - physiopathology (67) 67
glycosylated hemoglobin (67) 67
type 2 diabetes mellitus (66) 66
hypoglycemia (65) 65
metformin - administration & dosage (64) 64
body weight - drug effects (63) 63
glucagon-like peptide 1 - analogs & derivatives (63) 63
cardiac & cardiovascular systems (62) 62
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (967) 967
German (20) 20
French (11) 11
Spanish (5) 5
Hungarian (4) 4
Japanese (4) 4
Dutch (3) 3
Chinese (2) 2
Czech (2) 2
Swedish (2) 2
Italian (1) 1
Portuguese (1) 1
Russian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Diabetes Care, ISSN 0149-5992, 03/2016, Volume 39, Issue 3, pp. 455 - 464
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 05/2018, Volume 20, Issue 5, pp. 1111 - 1120
Aim: To evaluate the efficacy and safety of ertugliflozin and sitagliptin co-administration vs the individual agents in patients with type 2 diabetes who are... 
clinical trial | phase | study | type 2 diabetes | DPP‐IV | inhibitor | SGLT2 | III | glycaemic control | SGLT2 inhibitor | phase III study | DPP-IV inhibitor | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | MONOTHERAPY | EFFICACY | SAFETY | COMBINATION | BLOOD-PRESSURE | GLUCOSE COTRANSPORTER 2 | THERAPY | ENDOCRINOLOGY & METABOLISM | EMPAGLIFLOZIN | Glycated Hemoglobin A - analysis | Overweight - complications | Metformin - therapeutic use | Follow-Up Studies | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Dose-Response Relationship, Drug | Hypoglycemia - prevention & control | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Drug Therapy, Combination - adverse effects | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - administration & dosage | Female | Hypoglycemia - chemically induced | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Body Mass Index | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Double-Blind Method | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Diabetes Mellitus, Type 2 - blood | Sitagliptin Phosphate - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Sitagliptin Phosphate - adverse effects | Hypertension | Type 2 diabetes | Medical research | Care and treatment | Body weight | Clinical trials | Glycosylated hemoglobin | Mycoses | Complications and side effects | Analysis | Medicine, Experimental | Urinary tract infections | Hypoglycemic agents | Diabetes therapy | Diabetes mellitus | Hemoglobin | Blood pressure | Urinary tract | Diabetes | Metformin | Hypoglycemia | Diabetes mellitus (non-insulin dependent) | Index Medicus | DPP‐IV inhibitor | Original
Journal Article
Diabetic Medicine, ISSN 0742-3071, 04/2016, Volume 33, Issue 4, pp. 471 - 477
The study is unique in reporting resource use associated with severe hypoglycaemia from a randomized controlled trial setting, because resource use has... 
GLYCEMIC CONTROL | 26-WEEK | GLARGINE | NAIVE PATIENTS | ENDOCRINOLOGY & METABOLISM | NON-INFERIORITY TRIAL | OPEN-LABEL | TO-TARGET TRIAL | BASAL-BOLUS TREATMENT | TYPE-2 | DEGLUDEC/INSULIN ASPART | Hypoglycemia - therapy | Hypoglycemic Agents - economics | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Insulin Detemir - therapeutic use | Insulin Detemir - economics | Clinical Trials, Phase III as Topic | Hypoglycemic Agents - administration & dosage | Hypoglycemic Agents - therapeutic use | Sitagliptin Phosphate - administration & dosage | Costs and Cost Analysis | Administration, Oral | Drug Therapy, Combination - economics | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Insulin Aspart - economics | Insulin, Long-Acting - adverse effects | Insulin, Long-Acting - administration & dosage | Diabetes Mellitus, Type 1 - economics | Diabetes Mellitus, Type 1 - blood | Insulin, Long-Acting - therapeutic use | Hypoglycemic Agents - adverse effects | Insulin Aspart - adverse effects | Cohort Studies | Insulin Aspart - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Diabetes Mellitus, Type 2 - economics | Insulin, Long-Acting - economics | Dipeptidyl-Peptidase IV Inhibitors - economics | Insulin Glargine - administration & dosage | Drug Therapy, Combination - adverse effects | Insulin Aspart - administration & dosage | Insulin Detemir - administration & dosage | Insulin Detemir - adverse effects | Hypoglycemia - physiopathology | Adult | Hypoglycemia - economics | Hypoglycemia - chemically induced | Severity of Illness Index | Insulin Glargine - adverse effects | Drug Administration Schedule | Insulin Glargine - economics | Insulin Glargine - therapeutic use | Sitagliptin Phosphate - economics | Diabetes Mellitus, Type 1 - drug therapy | Diabetes Mellitus, Type 2 - blood | Health Care Costs | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drug Combinations | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Adults | Type 1 diabetes | Insulin | Analysis | Emergency medical care | Diabetes | Hypoglycemia | Index Medicus | Complications | Research
Journal Article
Diabetes Care, ISSN 0149-5992, 2016, Volume 39, Issue 12, pp. 2304 - 2310
OBJECTIVE To evaluate chronic kidney disease (CKD) and cardiovascular outcomes in TECOS (Clinical trial reg. no. NCT00790205, clinicaltrials. gov) participants... 
MORTALITY | INDIVIDUALS | ASSOCIATIONS | ALBUMINURIA | GLUCOSE | ENDOCRINOLOGY & METABOLISM | RISK | HYPERTENSION | LINAGLIPTIN | INTERVENTION | STAGE RENAL-DISEASE | Sitagliptin Phosphate - pharmacology | Cardiovascular Diseases - prevention & control | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Renal Insufficiency, Chronic - complications | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Diabetes Mellitus, Type 2 - epidemiology | Renal Insufficiency, Chronic - epidemiology | Cardiovascular Diseases - complications | Glomerular Filtration Rate - drug effects | Cardiovascular Diseases - epidemiology | Female | Diabetes Mellitus, Type 2 - complications | Kidney - physiopathology | Hypoglycemic Agents - therapeutic use | Kidney - drug effects | Double-Blind Method | Treatment Outcome | Renal Insufficiency, Chronic - physiopathology | Hypoglycemic Agents - pharmacology | Renal Insufficiency, Chronic - prevention & control | Diabetes Mellitus, Type 2 - physiopathology | Sitagliptin Phosphate - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Complications and side effects | Care and treatment | Kidney function tests | Sitagliptin | Dosage and administration | Research | Cardiovascular disease | Glycemic index | Diabetes | Medical treatment | Index Medicus
Journal Article
Diabetes Care, ISSN 0149-5992, 05/2017, Volume 40, Issue 5, pp. 647 - 654
OBJECTIVE To assess the risk of acute pancreatitis during treatment with glucagon-like peptide 1 receptor agonist dulaglutide, placebo, and active comparators... 
NON-INFERIORITY | TRIAL | METFORMIN | DAILY LIRAGLUTIDE | EXENATIDE TWICE | SITAGLIPTIN | ENDOCRINOLOGY & METABOLISM | RISK | OPEN-LABEL | THERAPIES | TYPE-2 DIABETES-MELLITUS | Metformin - therapeutic use | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Metformin - adverse effects | Female | Immunoglobulin Fc Fragments - therapeutic use | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Hypoglycemic Agents - therapeutic use | Acute Disease | Insulin Glargine - adverse effects | Venoms - adverse effects | Insulin Glargine - therapeutic use | Pancreatitis - chemically induced | Glucagon-Like Peptides - adverse effects | Venoms - therapeutic use | Sitagliptin Phosphate - therapeutic use | Glucagon-Like Peptides - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide-1 Receptor - agonists | Peptides - adverse effects | Peptides - therapeutic use | Sitagliptin Phosphate - adverse effects | Risk factors | Pancreatitis | Enzymes | Peptides | Glucagon | Adjudication | Medical treatment | Diabetes mellitus | Clinical trials | Exposure | Lipase | Insulin | Patients | Incidence | Amylases | Pain | Etiology | Risk assessment | Comparators | Safety engineering | Research design | Diabetes | Metformin | Pancreas | Glucagon-like peptide 1 | Index Medicus
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2018, Volume 41, Issue 2, pp. 153 - 157
Glucagon-like peptide-1 (GLP-1) receptor agonists (liraglutide, exenatide, lixisenatide) have recently been used as anti-diabetes drugs. We examined... 
pharmacokinetics | dipeptidyl peptidase-4 inhibitor | glucagon-like peptide-1 receptor agonist | target molecular binding occupancy | pharmacodynamics | Dipeptidyl peptidase-4 inhibitor | Pharmacodynamics | Pharmacokinetics | Glucagon-like peptide-1 receptor agonist | Target molecular binding occupancy | GLUCAGON-LIKE PEPTIDE-1 | PHARMACOLOGY & PHARMACY | PROMOTES SATIETY | Glycated Hemoglobin A - analysis | Hypoglycemic Agents - metabolism | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Peptides - pharmacokinetics | Nitriles - pharmacokinetics | Peptides - administration & dosage | Peptides - metabolism | Hypoglycemic Agents - administration & dosage | Pyrrolidines - metabolism | Adamantane - therapeutic use | Adamantane - administration & dosage | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Sitagliptin Phosphate - administration & dosage | Hyperglycemia - prevention & control | Hypoglycemic Agents - pharmacokinetics | Piperidines - administration & dosage | Piperidines - metabolism | Pyrrolidines - pharmacokinetics | Adamantane - metabolism | Models, Molecular | Uracil - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Liraglutide - therapeutic use | Venoms - therapeutic use | Ligands | Venoms - metabolism | Sitagliptin Phosphate - pharmacokinetics | Venoms - pharmacokinetics | Nitriles - therapeutic use | Liraglutide - metabolism | Sitagliptin Phosphate - metabolism | Pyrrolidines - administration & dosage | Diabetes Mellitus, Type 2 - metabolism | Molecular Targeted Therapy | Pyrrolidines - therapeutic use | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Glucagon-Like Peptide-1 Receptor - metabolism | Liraglutide - pharmacokinetics | Uracil - administration & dosage | Venoms - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - metabolism | Piperidines - pharmacokinetics | Adamantane - pharmacokinetics | Nitriles - metabolism | Reproducibility of Results | Diabetes Mellitus, Type 2 - blood | Algorithms | Piperidines - therapeutic use | Sitagliptin Phosphate - therapeutic use | Uracil - metabolism | Liraglutide - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Drug Monitoring | Uracil - pharmacokinetics | Glucagon-Like Peptide-1 Receptor - agonists | Peptides - therapeutic use | Uracil - analogs & derivatives | Binding | Drugs | Effectiveness | Peptidase | Glucagon | Diabetes mellitus | Theoretical analysis | Low level | Receptors | Inhibitors | Nitric oxide | Occupancy | Hemoglobin | Agonists | Glucagon-like peptide 1 | Drug dosages | Index Medicus
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 12/2018, Volume 28, Issue 23-24, pp. 3731 - 3735
Nitric oxide (NO) dysfunction has been found to be an important factor in both the development and progression of diabetic complications due to its many roles... 
Hypoglycemic | Dipeptidyl peptidase IV | Antioxidant | Nitric oxide | Sitagliptin derivatives | Anti-platelet aggregation | OXIDATIVE STRESS | POTENT | CHEMISTRY, MEDICINAL | INVOLVEMENT | CHEMISTRY, ORGANIC | DISCOVERY | Diabetes Mellitus, Experimental - drug therapy | Nitric Oxide Donors - chemistry | Sitagliptin Phosphate - pharmacology | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Platelet Aggregation Inhibitors - chemical synthesis | Platelet Aggregation Inhibitors - pharmacology | Nitric Oxide Donors - therapeutic use | Platelet Aggregation - drug effects | Nitric Oxide Donors - pharmacology | Diabetes Mellitus, Experimental - metabolism | Platelet Aggregation Inhibitors - therapeutic use | Hypoglycemic Agents - therapeutic use | Sitagliptin Phosphate - analogs & derivatives | Blood Glucose - analysis | Dipeptidyl-Peptidase IV Inhibitors - chemistry | Hypoglycemic Agents - chemistry | Mice, Inbred ICR | Hypoglycemic Agents - pharmacology | Dipeptidyl-Peptidase IV Inhibitors - chemical synthesis | Animals | Sitagliptin Phosphate - chemical synthesis | Hypoglycemic Agents - chemical synthesis | Platelet Aggregation Inhibitors - chemistry | Sitagliptin Phosphate - therapeutic use | Molecular Docking Simulation | Nitric Oxide Donors - chemical synthesis | Oxidative Stress - drug effects | Blood Glucose - metabolism | Nitric Oxide - metabolism | Antioxidants | Hypoglycemic agents | Metabolites | Blood sugar | Endothelium
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2018, Volume 20, Issue 2, pp. 378 - 388
Aims: To assess the safety and efficacy of monotherapy with once-weekly subcutaneous (s.c.) semaglutide vs sitagliptin in Japanese people with type 2 diabetes... 
GLP | sitagliptin | type 2 diabetes | GLP-1 | METFORMIN | ADD-ON | AMERICAN ASSOCIATION | HUMAN GLP-1 ANALOG | EXENATIDE | PHASE 3A | OPEN-LABEL | CLINICAL ENDOCRINOLOGISTS | LIRAGLUTIDE | ENDOCRINOLOGY & METABOLISM | ACUTE-PANCREATITIS | Glycated Hemoglobin A - analysis | Follow-Up Studies | Nausea - chemically induced | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Diarrhea - physiopathology | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glucagon-Like Peptides - administration & dosage | Humans | Nausea - physiopathology | Patient Dropouts | Weight Loss - drug effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Hypoglycemia - prevention & control | Diabetes Mellitus, Type 2 - ethnology | Glucagon-Like Peptide-1 Receptor - metabolism | Nausea - therapy | Injections, Subcutaneous | Hypoglycemia - chemically induced | Severity of Illness Index | Sitagliptin Phosphate - administration & dosage | Hyperglycemia - prevention & control | Drug Administration Schedule | Administration, Oral | Japan | Constipation - physiopathology | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Constipation - chemically induced | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Diarrhea - therapy | Constipation - therapy | Incretins - adverse effects | Sitagliptin Phosphate - therapeutic use | Glucagon-Like Peptides - therapeutic use | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide-1 Receptor - agonists | Incretins - administration & dosage | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Glycosylated hemoglobin | Hypoglycemic agents | Glucagon | Diabetes mellitus | Body weight | Hemoglobin | Diabetes | Safety | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Index Medicus | GLP‐1 | Original
Journal Article
Journal Article